How to prevent hair thinning and loss is a question that concerns a significant proportion of the UK population, from those noticing early shedding to those managing established pattern hair loss. The causes are wide-ranging — from androgenetic alopecia and nutritional deficiencies to thyroid disorders and scalp conditions — and the most effective prevention strategy depends on identifying the underlying trigger. This article outlines the common causes of hair thinning, when to seek medical advice, evidence-based prevention approaches, NHS and private treatment options, and the lifestyle and nutritional factors that support long-term hair health.

Common Causes of Hair Thinning and Loss in the UK

Androgenetic alopecia is the most common cause, affecting around half of men by age 50 and many women after the menopause; other causes include telogen effluvium, iron deficiency, thyroid disorders, and alopecia areata.

Hair thinning and loss affect a significant proportion of the UK population at some point in their lives, with causes ranging from genetic predisposition to underlying medical conditions. Understanding the root cause is the essential first step in knowing how to prevent hair thinning and loss effectively.

The most common cause in both men and women is androgenetic alopecia (pattern hair loss), which is driven by sensitivity to dihydrotestosterone (DHT), a derivative of testosterone. In men, this typically presents as a receding hairline or crown thinning; in women, it more often manifests as diffuse thinning across the top of the scalp. According to the British Association of Dermatologists (BAD), androgenetic alopecia affects around half of men by the age of 50 and is also common in women, particularly after the menopause.

Not sure if this is normal? Chat with one of our pharmacists →

Other frequently encountered causes include:

• Telogen effluvium — a temporary, diffuse shedding in which large numbers of hairs prematurely enter the resting (telogen) phase. Triggers include illness, surgery, childbirth, significant psychological stress, iron deficiency, thyroid dysfunction, and certain medications. Shedding typically becomes noticeable two to three months after the triggering event and usually resolves once the cause is addressed.

• Alopecia areata — an autoimmune condition causing patchy hair loss, estimated to affect approximately 2% of the UK population at some point in their lifetime (NICE CKS – Alopecia areata).

• Thyroid disorders — both hypothyroidism and hyperthyroidism can disrupt the hair growth cycle.

• Iron deficiency anaemia — one of the most common nutritional causes of diffuse hair thinning, particularly in women of reproductive age.

• Scalp conditions such as seborrhoeic dermatitis or tinea capitis (scalp ringworm). Tinea capitis is more common in children, is contagious, and requires prompt GP review and systemic antifungal treatment.

• Traction alopecia — gradual hair loss caused by sustained tension from tight hairstyles such as braids, extensions, or high ponytails.

• Medications including certain antidepressants, anticoagulants, retinoids, and chemotherapy agents.

Hormonal changes associated with the menopause, polycystic ovary syndrome (PCOS), and the postpartum period are also well-recognised contributors.

It is important to distinguish between non-scarring alopecias (such as androgenetic alopecia, telogen effluvium, and alopecia areata), where the follicle is preserved and regrowth is possible, and scarring alopecias (such as lichen planopilaris and frontal fibrosing alopecia), where irreversible follicle destruction can occur. Scarring alopecias require urgent specialist assessment. Because causes are so varied, a thorough clinical assessment is important before any treatment or prevention strategy is pursued.

When to See a GP or Dermatologist About Hair Loss

See a GP promptly if hair loss is sudden, patchy, accompanied by scalp inflammation, or associated with systemic symptoms such as fatigue or weight changes, as these may indicate a treatable underlying condition.

Whilst some degree of hair shedding is entirely normal — the average person loses between 50 and 100 hairs per day — certain patterns and symptoms warrant prompt medical attention. Knowing when to seek professional advice can make a meaningful difference to outcomes.

You should contact your GP if you notice:

• Sudden or rapid hair loss over a short period

• Patchy or circular bald areas on the scalp or elsewhere on the body

• Hair loss accompanied by scalp redness, scaling, itching, or pain

• Thinning that appears to be worsening progressively despite no obvious trigger

• Associated symptoms such as fatigue, unexplained weight changes, or irregular periods, which may suggest an underlying systemic condition

• Hair loss following a new medication, as your GP may be able to review your prescription

Seek prompt or expedited assessment if you notice signs of a scarring alopecia — such as redness, scaling, or follicular inflammation at the hairline or scalp — or if a child develops patchy scalp hair loss with scaling or broken hairs, which may indicate tinea capitis. Early treatment of scarring alopecias is essential to prevent permanent follicle loss.

Your GP will typically begin with a detailed history and examination, followed by targeted blood tests to exclude common treatable causes. In line with NICE CKS guidance on male and female pattern hair loss and alopecia areata, these may include a full blood count, serum ferritin, and thyroid function tests. Hormonal profiles (such as androgens and sex hormone-binding globulin) are not routine but may be considered in women where clinical features suggest an endocrine cause, such as PCOS or signs of hyperandrogenism. They are not generally indicated in men with typical pattern hair loss.

If the diagnosis remains unclear or the hair loss is severe, your GP may refer you to a consultant dermatologist via the NHS. Dermatologists can perform scalp biopsies, trichoscopy (dermoscopy of the scalp), and more specialist investigations. Private dermatology appointments are also widely available across the UK for those who prefer a faster route to diagnosis.

Evidence-Based Ways to Prevent Hair Thinning

Early use of topical minoxidil, correcting confirmed nutritional deficiencies, and avoiding traction hairstyles are the most evidence-based approaches; finasteride is an option for adult men with androgenetic alopecia under medical supervision.

It is important to note that androgenetic alopecia cannot be prevented, but early intervention may help to slow its progression. Prevention strategies for other causes are most effective when tailored to the underlying condition. Several evidence-based approaches are broadly applicable.

Minimising mechanical and chemical damage is a practical first step. Tight hairstyles such as high ponytails, braids, and extensions can cause traction alopecia — a form of gradual hair loss resulting from sustained tension on the follicle. Reducing heat styling, avoiding harsh chemical treatments, and using a wide-toothed comb on wet hair can all help preserve hair shaft integrity.

Addressing nutritional deficiencies is equally important. Ensuring adequate intake of iron, zinc, and protein supports the normal hair growth cycle. Supplementation should only be pursued where a deficiency has been confirmed by blood tests, as excessive intake of certain nutrients — notably vitamin A — has itself been associated with hair loss. Biotin deficiency is rare in people eating a varied diet, and evidence for biotin supplementation in the absence of confirmed deficiency is poor; it may also interfere with certain laboratory assays, so supplementation should be discussed with a clinician.

For those with androgenetic alopecia, early pharmacological intervention offers the best chance of slowing progression:

• Topical minoxidil is available over the counter in the UK (e.g., as a 2% or 5% solution or foam). It prolongs the anagen (growth) phase and increases follicular size. A consistent response typically takes three to six months of regular use, and treatment must be continued to maintain benefit. Common adverse effects include initial increased shedding (which usually settles), scalp irritation, and, rarely, unwanted facial hair growth. People with cardiovascular conditions should seek medical advice before use. Refer to the product Summary of Product Characteristics (SmPC) on the Electronic Medicines Compendium (EMC) for full prescribing information.

• Finasteride 1 mg (prescription-only for adult men in the UK) inhibits the 5-alpha reductase enzyme, reducing DHT levels at the follicle. It is not licensed for use in women and is contraindicated in women of childbearing potential due to the risk of feminisation of a male foetus; pregnant women should not handle crushed or broken tablets. The MHRA has issued Drug Safety Updates highlighting risks of persistent sexual dysfunction (including reduced libido, ejaculatory disorders, and erectile dysfunction) and psychiatric adverse effects (including depression and, rarely, suicidal ideation) in some men. Patients should be issued with the MHRA Patient Alert Card and advised to seek prompt medical review if they experience mood changes or persistent sexual side effects. Suspected adverse reactions should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). Refer to the finasteride SmPC on the EMC for full safety information.

Managing psychological stress through evidence-based techniques — including cognitive behavioural therapy (CBT), regular physical activity, and adequate sleep — supports general wellbeing and may be helpful for stress-related shedding. However, stress management is not a disease-modifying therapy for androgenetic alopecia.

Treatments Available on the NHS and Privately

NHS treatment is largely restricted to hair loss caused by underlying medical conditions; privately, options include oral minoxidil, dutasteride, PRP therapy, low-level laser therapy, and hair transplant surgery.

The availability of hair loss treatments on the NHS is limited, as most cases of androgenetic alopecia are considered a cosmetic concern rather than a medical one. However, where hair loss is secondary to a treatable condition — such as thyroid disease, iron deficiency, or alopecia areata — the underlying condition will be managed through standard NHS pathways.

NHS-available treatments may include:

• Topical or intralesional corticosteroids for alopecia areata, to suppress the localised autoimmune response

• Immunotherapy with diphencyprone (DPCP) for extensive alopecia areata, available at specialist dermatology centres

• JAK inhibitors — ritlecitinib and baricitinib have been appraised by NICE for severe alopecia areata in adults and adolescents meeting specific eligibility criteria. Patients should check the latest NICE Technology Appraisals and discuss NHS availability with their dermatologist, as commissioning may vary.

• Treatment of underlying conditions (e.g., levothyroxine for hypothyroidism, iron supplementation for confirmed deficiency anaemia)

For androgenetic alopecia specifically, NHS prescribing of finasteride or dutasteride is uncommon outside specialist settings, and topical minoxidil is generally purchased over the counter.

Privately available options are considerably broader and include:

• Oral minoxidil at low doses, used off-label (its UK licence is for hypertension, not hair loss) for both male and female pattern hair loss under medical supervision. Key risks include hypotension, tachycardia, fluid retention, and hypertrichosis. Blood pressure monitoring is required, and it is contraindicated in pregnancy. Informed consent and medical oversight are essential.

• Dutasteride, which is also off-label for hair loss in the UK and is not routinely commissioned on the NHS. It carries similar risks to finasteride, including teratogenicity, and should only be used under specialist supervision.

• Platelet-rich plasma (PRP) therapy, which involves injecting concentrated growth factors from the patient's own blood into the scalp — evidence is emerging but not yet definitive.

• Low-level laser therapy (LLLT) devices, which may carry UKCA or CE marking. It is important to note that such marking indicates conformity with safety and technical standards but does not confirm clinical effectiveness; evidence quality for LLLT in hair loss remains variable.

• Hair transplant surgery (follicular unit extraction, FUE), which offers a long-term solution for suitable candidates but is costly and not available on the NHS for cosmetic indications.

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates licensed medicines and medical devices in the UK. (The European Medicines Agency, EMA, regulates medicines in the EU and no longer has jurisdiction in the UK following Brexit.) Patients should be cautious of unregulated products making unsubstantiated claims, and should report concerns about unlicensed products to the MHRA.

Lifestyle and Nutritional Factors That Affect Hair Health

A diet adequate in protein, iron, zinc, and vitamins D and B12 supports the hair growth cycle; smoking cessation, quality sleep, and stress management also contribute to scalp and follicle health.

Hair follicles are among the most metabolically active structures in the body, making them particularly sensitive to nutritional status, hormonal balance, and overall physical health. Optimising lifestyle factors forms an important and often underestimated component of any strategy for how to prevent hair thinning and loss.

Diet and nutrition play a central role. A balanced diet rich in the following nutrients supports healthy hair growth:

• Protein — hair is composed almost entirely of keratin, a structural protein; inadequate dietary protein can trigger diffuse shedding

• Iron and ferritin — iron deficiency is a well-established cause of hair thinning; testing and correcting a confirmed deficiency is recommended rather than routine supplementation. Good dietary sources include red meat, lentils, and fortified cereals. The threshold at which ferritin levels contribute to hair loss is not standardised, so interpretation should be guided by a clinician.

• Zinc — supports follicle repair and protein synthesis; found in shellfish, seeds, and wholegrains. Supplementation is appropriate only for confirmed deficiency.

• Omega-3 fatty acids — found in oily fish, walnuts, and flaxseed. Some evidence suggests a possible role in supporting scalp health, but the evidence base for hair growth specifically is limited and no causal relationship has been established.

• Vitamins D and B12 — deficiencies in both have been associated with hair loss, particularly in those following plant-based diets. Testing and treating a confirmed deficiency is advisable; routine supplementation without confirmed deficiency is not currently recommended for hair loss specifically.

Smoking has been independently associated with androgenetic alopecia in several studies, likely due to its effects on microcirculation and oxidative stress at the follicle level. Smoking cessation is advisable both for general health and hair health.

Sleep quality and stress regulation should not be overlooked. Chronic sleep deprivation elevates cortisol levels, which may disrupt the hair growth cycle. Aiming for 7–9 hours of quality sleep per night, alongside regular moderate exercise, supports hormonal balance and reduces systemic inflammation.

Finally, scalp hygiene matters. Regular, gentle cleansing removes sebum and product residue that may affect scalp comfort. Those with scalp conditions such as seborrhoeic dermatitis may benefit from medicated shampoos; options available over the counter in the UK include ketoconazole 2%, selenium sulphide, coal tar, and piroctone olamine-containing formulations. Note that zinc pyrithione, previously a common ingredient in anti-dandruff shampoos, has been subject to regulatory restrictions in the UK and EU and is no longer widely available in leave-on or rinse-off cosmetic products; patients should check current product labelling. For persistent or severe scalp conditions, a GP or dermatologist can advise on appropriate treatment.

Frequently Asked Questions